重症肝病合并侵袭性真菌病的抗真菌治疗

肝脏 ›› 2021, Vol. 26 ›› Issue (7): 804-807.

重症肝病合并侵袭性真菌病的抗真菌治疗

陈丹俐, 陈金军

510515 广州南方医科大学附属南方医院肝病中心

收稿日期:2020-12-11 出版日期:2021-07-31 发布日期:2021-09-02
通讯作者: 陈金军,Email:chjj@smu.edu.cn
基金资助:
国家科技部重大专项(2018ZX10723203,2018ZX10302206)

Received:2020-12-11 Online:2021-07-31 Published:2021-09-02

摘要/Abstract

摘要： 重症肝病合并侵袭性真菌感染的发病率逐渐增加,但是临床表现缺乏特异性,导致诊治不及时,短期死亡率高。一旦确诊应尽早启动抗真菌治疗。目前抗真菌方案为药物治疗、肠道微生态调节、血液净化及免疫调节治疗,其中药物治疗占主导地位。不同抗真菌药物具有不同的抗菌谱、适应证及副作用,并且针对不同肝功能损害程度的患者,药物剂量需要进行相应的调整。临床上常用抗真菌药物为伏立康唑、卡泊芬净、米卡芬净。深入了解不同抗真菌药物的作用特点可更好地指导临床应用,对提高临床抗真菌感染的疗效至关重要。目前伏立康唑是有效且安全的,但治疗剂量尚未统一,仍需要大数据的验证。

关键词: 重症肝病, 侵袭性真菌病, 抗真菌药物, 伏立康唑, 血药浓度

陈丹俐, 陈金军. 重症肝病合并侵袭性真菌病的抗真菌治疗[J]. 肝脏, 2021, 26(7): 804-807.

参考文献

[1] Arroyo V,Moreau R,Kamath PS,et al. Acute-on-chronic liver failure in cirrhosis. Nat Rev Dis Primers,2016,2:16041.
[2] Fernández J,Acevedo J,Wiest R,et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence,,characteristics and impact on prognosis. Gut,2018,67:1870-1880.
[3] De Pauw B,Walsh TJ,Donnelly JP,et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis,2008,46:1813-1821.
[4] 陈韬,宁琴. 终末期肝病合并感染诊治专家共识. 临床肝胆病杂志,2018,34:1862-1872.
[5] 张昕,彭小玲,李兆芳. ICU患者侵袭性真菌感染的诊断方法研究. 中华保健医学杂志,2020,22:209-211.
[6] Chen YC,Huang TS,Wang YC,et al. Effect of prophylactic antifungal protocols on the prognosis of liver transplantation:a propensity score matching and multistate model approach. Biomed Res Int,2016,2016:6212503.
[7] 余婷婷,张伦理,葛善飞,等. 抗真菌药物在采用糖皮质激素治疗慢加急性(亚急性)肝衰竭患者中的预防作用. 中华传染病杂志,2019:534-539.
[8] Annie W-B,Jane K. Systemic antifungal therapy:new options,new challenges. Pharmacotherapy,2003:23:1441-1462.
[9] 凌子. 抗真菌良药--咪唑类药物. 中国社区医师,2004:19.
[10] Wang T,Zhu H,Sun J,et al. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. Int J Antimicrob Agents,2014,44:436-442.
[11] Li ZW,Peng FH,Yan M,et al. Impact of CYP2C19 genotype and liver function on voriconazole pharmacokinetics in renal transplant recipients. Ther Drug Monit,2017,39:422-428.
[12] Seyedmousavi S,Mouton JW,Verweij PE,et al. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Expert Rev Anti Infect Ther,2013,11:931-941.
[13] Ashbee HR,Barnes RA,Johnson EM,et al. Therapeutic drug monitoring(TDM)of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother,2014,69:1162-1176.
[14] Patterson TF,Thompson GR 3rd,Denning DW,et al. Executive Summary:Practice Guidelines for the Diagnosis and Management of Aspergillosis:2016 Update by the Infectious Diseases Society of America. Clin Infect Dis, 2016,63:e1-e60.
[15] Wang T,Yan M,Tang D,et al. A retrospective, multicenter study of voriconazole trough concentrations and safety in patients with Child-Pugh class C cirrhosis. J Clin Pharm Ther,2018,43:849-854.
[16] Dolton MJ,Ray JE,Chen SC,et al. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother,2012,56:4793-4799.
[17] Gao J,Zhang Q,Wu Y,et al. Improving survival of acute-on-chronic liver failure patients complicated with invasive pulmonary aspergillosis. Sci Rep,2018,8:876.
[18] Kung HC,Huang PY,Chen WT,et al. 2016 guidelines for the use of antifungal agents in patients with invasive fungal diseases in Taiwan. J Microbiol Immunol Infect,2018,51:1-17.
[19] Pappas PG,Kauffman CA,Andes DR,et al. Clinical Practice Guideline for the Management of Candidiasis:2016 Update by the Infectious Diseases Society of America. Clin Infect Dis,2016,62:e1-50.
[20] Ullmann AJ,Cornely OA,Donnelly JP,et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012:developing European guidelines in clinical microbiology and infectious diseases. Clin Microbiol Infect, 2012,18 Suppl 7:1-8.
[21] 中华医学会重症医学分会. 重症患者侵袭性真菌感染诊断与治疗指南(2007). 中华内科杂志,2007,46:960-966.
[22] 华俊国,张丽. 三氮唑类抗真菌药物的研究进展. 江苏化工,2006:15-19.
[23] 于晓佳,周虹,崔向丽. 注射用两性霉素B致肝损害的药学监护. 中国临床药理学杂志,2017,33:1475-1476,1490.
[24] Yamamoto ES,Jesus JA,Bezerra-Souza A,et al. Activity of Fenticonazole,Tioconazole and Nystatin on New World Leishmania Species. Curr Top Med Chem,2018,18:2338-2346.
[25] 徐和平,刘伟民. 深部真菌感染药敏试验结果与临床疗效对比分析. 海峡药学,2009,21:108-109.
[26] Ademe M. Immunomodulation for the treatment of fungal infections:opportunities and challenges. Front Cell Infect Microbiol,2020,10:469.
[27] Salgueiro LR,Cavaleiro C,Pinto E,et al. Chemical composition and antifungal activity of the essential oil of origanum virens on Candida species. Planta Med,2003,69:871-874.
[28] Liu S,Hou Y,Chen X,et al. Combination of fluconazole with non-antifungal agents:a promising approach to cope with resistant Candida albicans infections and insight into new antifungal agent discovery. Int J Antimicrob Agents,2014,43:395-402.
[29] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版). 实用肝脏病杂志,2019,22:164-171.
[30] 魏琦,杨静楠,何学良,等. 粪便菌群移植在慢性乙肝治疗中的作用及机制. 中国病理生理杂志,2020,36:1833-1843.
[31] Ronco C,Tetta C,Mariano F,et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis:the peak concentration hypothesis. Artif Organs,2003,27:792-801.
[32] Zhou F,Peng Z,Murugan R,et al. Blood purification and mortality in sepsis:a meta-analysis of randomized trials. Crit Care Med,2013,41:2209-2220.